Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Modern diagnostic capabilities of neonatal screening for primary immunodeficiencies in newborns

  • Khalturina, Evgenia Olegovna (Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)) ;
  • Degtyareva, Natalia Dmitrievna (Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)) ;
  • Bairashevskaia, Anastasiia Vasi'evna (Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)) ;
  • Mulenkova, Alena Valerievna (Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)) ;
  • Degtyareva, Anna Vladimirovna (Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University))
  • Received : 2020.07.19
  • Accepted : 2021.02.05
  • Published : 2021.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Population screening of newborns is an extremely important and informative diagnostic approach that allows early identification of babies who are predisposed to the development of a number of serious diseases. Some of these diseases are known and have effective treatment methods. Neonatal screening enables the early diagnosis and subsequent timely initiation of therapy. This helps to prevent serious complications and reduce the percentage of disability and deaths among newborns and young children. Primary immunodeficiency diseases and primary immunodeficiency syndrome (PIDS) are a heterogeneous group of diseases and conditions based on impaired immune system function associated with developmental defects and characterized by various combinations of recurrent infections, development of autoimmune and lymphoproliferative syndromes (genetic defects in apoptosis, gene mutation Fas receptor or ligand), granulomatous process, and malignant neoplasms. Most of these diseases manifest in infancy and lead to serious illness, disability, and high mortality rates. Until recently, it was impossible to identify children with PIDS before the onset of the first clinical symptoms, which are usually accompanied by complications in the form of severe coinfections of a viral-bacterial-fungal etiology. Modern advances in medical laboratory technology have allowed the identification of children with severe PIDS, manifested by T- and/or B-cell lymphopenia and other disorders of the immune system. This review discusses the main existing strategies and directions used in PIDS screening programs for newborns, including approaches to screening based on excision of T-cell receptors and kappa-recombination excision circles, as well as the potential role and place of next-generation sequencing technology to increase the diagnostic accuracy of these diseases.

Keywords

References

  1. Order of the Moscow Department of Health No. 935 dated 26.12.2017 "On Amending the Order of the Moscow Department of Health from 12.03.2015 No 183". Available from: https://base.garant.ru/49621558/.
  2. Puck JM; SCID Newborn Screening Working Group. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol 2007;120:760-8. https://doi.org/10.1016/j.jaci.2007.08.043
  3. Brown L, Xu-Bayford J, Allwood Z, Slatter M, Cant A, Davies EG, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 2011;117:3243-6. https://doi.org/10.1182/blood-2010-08-300384
  4. Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab 2011;104:383-9. https://doi.org/10.1016/j.ymgme.2011.07.007
  5. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 20002009. N Engl J Med 2014;371:434-46. https://doi.org/10.1056/NEJMoa1401177
  6. McGhee SA, Stiehm ER, McCabe ER. Potential costs and benefits of newborn screening for severe combined immunodeficiency. J Pediatr 2005;147:603-8. https://doi.org/10.1016/j.jpeds.2005.06.001
  7. Madkaikar MR, Shabrish S, Kulkarni M, Aluri J, Dalvi A, Kelkar M, et al. Application of flow cytometry in primary immunodeficiencies: experience from India. Front Immunol 2019;10:1248. https://doi.org/10.3389/fimmu.2019.01248
  8. Kanegane H, Hoshino A, Okano T, Yasumi T, Wada T, Takada H, et al. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergol Int 2018;67:43-54. https://doi.org/10.1016/j.alit.2017.06.003
  9. Korsunskiy I, Blyuss O, Gordukova M, Davydova N, Gordleeva S, Molchanov R, et al. TREC and KREC levels as a predictors of lymphocyte subpopulations measured by flow cytometry. Front Physiol 2019;9:1877. https://doi.org/10.3389/fphys.2018.01877
  10. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, et al. Primary immunodeficiency diseases: an update on the Classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency 2015. J Clin Immunol 2015;35:696-726. https://doi.org/10.1007/s10875-015-0201-1
  11. Guerrerio AL, Frischmeyer-Guerrerio PA, Lederman HM, Oliva-Hemker M. Recognizing gastrointestinal and hepatic manifestations of primary immunodeficiency diseases. J Pediatr Gastroenterol Nutr 2010;51:54855.
  12. Szabo MZ. Rheumatological manifestations in primary immunodeficiency diseases. Orv Hetil 2018;159:919-28. (Russian) https://doi.org/10.1556/650.2018.31084
  13. Sillevis Smitt JH, Kuijpers TW. Cutaneous manifestations of primary immunodeficiency. Curr Opin Pediatr 2013;25:492-7. https://doi.org/10.1097/MOP.0b013e3283623b9f
  14. Gaspar HB, Hammarstrom L, Mahlaoui N, Borte M, Borte S. The case for mandatory newborn screening for severe combined immunodeficiency (SCID). J Clin Immunol 2014;34:393-7. https://doi.org/10.1007/s10875-014-0029-0
  15. Chavoshzadeh Z, Hashemitari A, Darougar S. Neurological manifestations of primary immunodeficiencies. Iran J Child Neurol 2018;12:7-23.
  16. King JR, Hammarstrom L. Newborn screening for primary immunodeficiency diseases: history, current and future practice. J Clin Immunol 2018;38:56-66. https://doi.org/10.1007/s10875-017-0455-x
  17. Somech R. T-cell receptor excision circles in primary immunodeficiencies and other T-cell immune disorders. Curr Opin Allergy Clin Immunol 2011;11:517-24. https://doi.org/10.1097/ACI.0b013e32834c233a
  18. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-5. https://doi.org/10.1038/25374
  19. Lorenzi AR, Patterson AM, Pratt A, Jefferson M, Chapman CE, Ponchel F, et al. Determination of thymic function directly from peripheral blood: a validated modification to an established method. J Immunol Methods 2008;339:185-94. https://doi.org/10.1016/j.jim.2008.09.013
  20. Haitov RM, Pinegin BV. Immunodeficiencies: diagnosis and immunotherapy. Lechashchij Vrach 1999;2:63-69. (Russian)
  21. Puck JM. The case for newborn screening for severe combined immunodeficiency and related disorders. Ann N Y Acad Sci 2011;1246:108-17. https://doi.org/10.1111/j.1749-6632.2011.06346.x
  22. Borte S, Wang N, Oskarsdottir S, von Dobeln U, Hammarstrom L. Newborn screening for primary immunodeficiencies: beyond SCID and XLA. Ann N Y Acad Sci 2011;1246:118-30. https://doi.org/10.1111/j.1749-6632.2011.06350.x
  23. Lindegren ML, Kobrynski L, Rasmussen SA, Moore CA, Grosse SD, Vanderford ML, et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm Rep 2004;53(RR-1):1-29.
  24. Somech R, Lev A, Simon AJ, Korn D, Garty BZ, Amariglio N, et al. Newborn screening for severe T and B cell immunodeficiency in Israel: a pilot study. Isr Med Assoc J 2013;15:404-9.
  25. Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA 2009;302:2465-70. https://doi.org/10.1001/jama.2009.1806
  26. Baker MW, Laessig RH, Katcher ML, Routes JM, Grossman WJ, Verbsky J, et al. Implementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program. Public Health Rep 2010;125 Suppl 2(Suppl 2):88-95.
  27. Modell V, Orange JS, Quinn J, Modell F. Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes. Immunol Res 2018;66:367-80. https://doi.org/10.1007/s12026-018-8996-5
  28. Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol 2018;38:129-43. https://doi.org/10.1007/s10875-017-0465-8
  29. Buckley RH. The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol 2012;129:597-604; quiz 6056. https://doi.org/10.1016/j.jaci.2011.12.964
  30. van der Burg M, Mahlaoui N, Gaspar HB, Pai SY. Universal newborn screening for severe combined immunodeficiency (SCID). Front Pediatr 2019;7:373. https://doi.org/10.3389/fped.2019.00373
  31. Institute for Quality and Efficiency in Health Care. Newborn screening for severe immunodeficiency: advantage in the case of early treatment [Internet]. ScienceDaily; 2017 [cited 2017 Jan 30] Available from: https://www.sciencedaily.com/releases/2017/01/170130111023.htm.
  32. Deryabina SS, Tuzankina IA, Vlasova EV, Bolkov MA, Shershnyov VN. Neonatal screening for severe combined immune deficiency in Russia: beautiful far away or tomorrow's reality? Voprosy Sovremen Pediatr 2017;16:59-66. (Russian) https://doi.org/10.15690/vsp.v16i1.1696
  33. Gordukova MA, Oskorbin IP, Mishukova OV, Zimin SB, Zinov'eva NV, Davydova NV, et al. Development of real-time multiplex PCR for the quantitative determination of TREC' and KREC' in whole blood and in dried blood spots. Medicinskaya Immunol 2015;17:467-478. (Russian) https://doi.org/10.15789/1563-0625-2015-5-467-478
  34. Deryabina SS, Tuzankina IA, Vlasova EV, Shershnev VN. Quantification of the ring structures of TREC and KREC in children with impaired immune system function in the first year of life. Meditsinskaya Genetika 2015;2:53-54. (Russian)
  35. Deryabina SS, Tuzankina IA, Vlasova EV, Lavrina SG, Shershnev VN. Retrospective diagnosis of primary immunodeficiencies for children in Sverdlovsk Region. Med Immunol (Rissia) 2016;18:583-588. https://doi.org/10.15789/1563-0625-2016-6-583-588
  36. Verbsky JW, Baker MW, Grossman WJ, Hintermeyer M, Dasu T, Bonacci B, et al. Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J Clin Immunol 2012;32:82-8. https://doi.org/10.1007/s10875-011-9609-4
  37. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014;312:729-38. https://doi.org/10.1001/jama.2014.9132
  38. Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol 2013;132:140-50. https://doi.org/10.1016/j.jaci.2013.04.024
  39. Vogel BH, Bonagura V, Weinberg GA, Ballow M, Isabelle J, DiAntonio L, et al. Newborn screening for SCID in New York State: experience from the first two years. J Clin Immunol 2014;34:289-303. https://doi.org/10.1007/s10875-014-0006-7
  40. Picard C, Fischer A. Contribution of high-throughput DNA sequencing to the study of primary immunodeficiencies. Eur J Immunol 2014;44:285461.
  41. Chou J, Ohsumi TK, Geha RS. Use of whole exome and genome sequencing in the identification of genetic causes of primary immunodeficiencies. Curr Opin Allergy Clin Immunol 2012;12:623-8. https://doi.org/10.1097/ACI.0b013e3283588ca6
  42. Hsu AP, Fleisher TA, Niemela JE. Mutation analysis in primary immunodeficiency diseases: case studies. Curr Opin Allergy Clin Immunol 2009;9:517-24. https://doi.org/10.1097/ACI.0b013e3283328f59
  43. Oliveira JB, Fleisher TA. Molecular- and flow cytometry-based diagnosis of primary immunodeficiency disorders. Curr Allergy Asthma Rep 2010;10:460-7. https://doi.org/10.1007/s11882-010-0137-8
  44. Weiss MM, Van der Zwaag B, Jongbloed JD, Vogel MJ, Bruggenwirth HT, Lekanne Deprez RH, et al. Best practice guidelines for the use of next-generation sequencing applications in genome diagnostics: a national collaborative study of Dutch genome diagnostic laboratories. Hum Mutat 2013;34:1313-21. https://doi.org/10.1002/humu.22368
  45. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010;11:31-46. https://doi.org/10.1038/nrg2626
  46. Nijman IJ, van Montfrans JM, Hoogstraat M, Boes ML, van de Corput L, Renner ED, et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. J Allergy Clin Immunol 2014;133:529-34. https://doi.org/10.1016/j.jaci.2013.08.032
  47. Ghosh S, Krux F, Binder V, Gombert M, Niehues T, Feyen O, et al. Array-based sequence capture and next-generation sequencing for the identification of primary immunodeficiencies. Scand J Immunol 2012;75:350-4. https://doi.org/10.1111/j.1365-3083.2011.02658.x
  48. Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can exome sequencing do for you? J Med Genet 2011;48:580-9. https://doi.org/10.1136/jmedgenet-2011-100223
  49. Nowrousian M. Next-generation sequencing techniques for eukaryotic microorganisms: sequencing-based solutions to biological problems. Eukaryot Cell 2010;9:1300-10. https://doi.org/10.1128/EC.00123-10
  50. Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol 2018;38:96-128. https://doi.org/10.1007/s10875-017-0464-9
  51. Sun J, Yang L, Lu Y, Wang H, Peng X, Dong X, et al. Screening for primary immunodeficiency diseases by next-generation sequencing in early life. Clin Transl Immunology 2020;9:e1138.
  52. Dorsey MJ, Puck JM. Newborn Screening for Severe Combined Immunodeficiency in the United States: Lessons Learned. Immunol Allergy Clin North Am 2019;39:1-11. https://doi.org/10.1016/j.iac.2018.08.002
  53. Amatuni GS, Currier RJ, Church JA, Bishop T, Grimbacher E, Nguyen AA, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California, 2010-2017. Pediatrics 2019;143:e20182300. https://doi.org/10.1542/peds.2018-2300
  54. Hammarstrom L. Primary immunodeficiencies screening: neonatal screening for T/B cell disorders - a triplex PCR method for quantitation of TRECs and KRECs in newborns. Clin Exp Immunol 2014;178 Suppl 1 (Suppl 1):14-5. https://doi.org/10.1111/cei.12494